Lupin acquires Nanomi BV
The acquisition will help Lupin to expand its business in patented products.
Mumbai, February 6, 2014: The Mumbai-based drug firm, Lupin Ltd recently announced that it is acquiring Netherland-based injectable company Nanomi BV. The acquisition is expected to help the company to expand its business in patented products.
The Indian drug firm said that the expertise of Nanomi in the nano and micro particles will help it to look at new disease portfolios in the injectable segment.
The company also said that it wants to operate in an area of healthcare that has high technology barrier and limited competition. The acquisition is expected to help the company to focus on the specific therapeutic areas. Lupin has already shown phenomenal growth in its US operations with a 42 per cent growth in the third quarter net profit ending December to Rs 476 crore.
The growth in the US market was largely driven by new products launches in the US such as Trilipix, used for treating high cholesterol and Cymbalta.